Cargando…

Abstract #1403045: Thyroiditis Post COVID-19 mRNA Booster Dose Vaccination

Detalles Bibliográficos
Autor principal:	Seow, Cherng Jye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156632/ http://dx.doi.org/10.1016/j.eprac.2023.03.226

Ejemplares similares

Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster
por: Singh, Arminder, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Abstract #1405060: Subacute Thyroiditis Following Vaccination with COVID-19 mRNA Vaccine
por: Waheed, Najeeb, et al.
Publicado: (2023)

mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks, and Coverage
por: Nashwan, Abdulqadir J., et al.
Publicado: (2022)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
por: Mengesha, Bethlehem, et al.
Publicado: (2022)

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
por: Grewal, Ramandip, et al.
Publicado: (2023)

Imaging of Myocarditis Following mRNA COVID-19 Booster Vaccination
por: Sanchez Tijmes, Felipe, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Booster Effect of a Third mRNA-Based COVID-19 Vaccine Dose in Patients with Myeloid Malignancies
por: Mori, Akio, et al.
Publicado: (2022)

Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
por: Grewal, Ramandip, et al.
Publicado: (2023)

Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization
por: AlOtaibi, Ibtihal, et al.
Publicado: (2023)

Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2023)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine
por: Chung, Hyemin, et al.
Publicado: (2022)

Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience()
por: Bertozzi, Andrea, et al.
Publicado: (2023)

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
por: Kuhlmann, Constanze, et al.
Publicado: (2022)

Subacute thyroiditis post-Pfizer-BioNTech mRNA vaccination for COVID-19
por: Khan, Farooq, et al.
Publicado: (2021)

Thyroiditis after mRNA Vaccination for COVID-19
por: Saha, Arunava, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
por: Yigit, Metin, et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study
por: Ferrara, Pietro, et al.
Publicado: (2023)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination
por: Langerak, T., et al.
Publicado: (2022)

Painless thyroiditis following mRNA vaccination for COVID-19
por: Nakaizumi, Nobuhiko, et al.
Publicado: (2022)

Subacute Thyroiditis After mRNA Vaccine for Covid-19
por: Franquemont, Stephanie, et al.
Publicado: (2021)

mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
por: Azzolini, Elena, et al.
Publicado: (2022)

Acute panuveitis after COVID-19 mRNA booster vaccination following cataract surgery
por: Kung, Timothy-Paul H., et al.
Publicado: (2022)

Side Effects after mRNA COVID-19 Vaccine as a Booster in Health Workers
por: Pakki, Temmasonge Radi, et al.
Publicado: (2022)

mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia
por: Li, Rui, et al.
Publicado: (2023)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
por: Das, Rituparna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8fc5l43jtveq33m8fu8bkqcf91